Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT00199862
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
Overview
The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.
Sponsor
Memorial Sloan Kettering Cancer Center
Phase
N/A
Contacts
Neeta Pandit-Taskar, MD (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT00199862Drug / Compound
huA33
Isotope(s):
IODINE-124
Radioisotope: I-124
Theranostic Role: Imaging
T1/2 (Half-Life): 4.2 Days
Decay Mode: Electron Capture 74.4% and Positron Emission 25.6%
Energy: 2.138 MeV
Decay Daughters: Tellurium-124
Target(s):
- GPA33
Ligand Class: Antibodies
Eligibility
Inclusion
- Patients must be candidates for clinically indicated surgery/biopsy for primary/metastatic colorectal cancer
- Primary or metastatic colorectal carcinoma, histologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC).
Exclusion
- Active CNS tumor involvement. Previous treatment with A33 or its fragment and/or a positive test for huA33 HAHA.
Share your feedback
Help us improve your experience